Daito Pharmaceutical Co., Ltd. Statistics
Want to see JP:4577 full AI Analyst Report?
Daito Pharmaceutical Co., Ltd. (4577) Stock Statistics & Valuation Metrics
Total Valuation
Daito Pharmaceutical Co., Ltd. has a market cap or net worth of JPY 37.62B. The enterprise value is JPY 44.71B.
- Market Cap
- JPY 37.62B
- Enterprise Value
- JPY 44.71B
Share Statistics
Daito Pharmaceutical Co., Ltd. has 28,854,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 28,854,880
- Owned by Insiders
- ―
- Owned by Institutions
- 9.38%
Financial Efficiency
Daito Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 4.48%.
- Return on Equity (ROE)
- 0.06
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- 4.48%
- Return on Capital Employed (ROCE)
- 0.06
- Revenue Per Employee
- 46.68M
- Profits Per Employee
- 2.91M
- Employee Count
- 1,085
- Asset Turnover
- 0.69
- Inventory Turnover
- 2.48
Valuation Ratios
The current PE Ratio of Daito Pharmaceutical Co., Ltd. is 12.05. Daito Pharmaceutical Co., Ltd.’s PEG ratio is 0.18.
- PE Ratio
- 12.05
- PS Ratio
- 0.75
- PB Ratio
- 0.71
- Price to FCF
- 6.71
- Price to Operating Cash Flow
- 3.98
- PEG Ratio
- 0.18
Income Statement
In the last 12 months, Daito Pharmaceutical Co., Ltd. had revenue of 50.65B and earned 3.16B in profits. Earnings per share was 107.46.
- Revenue
- 50.65B
- Gross Profit
- 9.90B
- Operating Income
- 3.64B
- Pretax Income
- 4.07B
- Net Income
- 3.16B
- EBITDA
- 8.02B
- Earnings Per Share (EPS)
- 107.46
Cash Flow
In the last 12 months, operating cash flow was 9.38B and capital expenditures -3.85B, giving a free cash flow of 5.53B billion.
- Operating Cash Flow
- 9.38B
- Free Cash Flow
- 5.53B
- Free Cash Flow per Share
- 194.50
Dividends & Yields
Daito Pharmaceutical Co., Ltd. pays an annual dividend of JPY 20.00, resulting in a dividend yield of 3.07%
- Dividend Per Share
- JPY 20.00
- Dividend Yield
- 3.07%
- Payout Ratio
- 57.02%
- Free Cash Flow Yield
- 14.96%
- Earnings Yield
- 8.52%
Stock Price Statistics
- Beta
- 0.22
- 52-Week Price Change
- 6.02%
- 50-Day Moving Average
- 1319.44
- 200-Day Moving Average
- 1308.86
- Relative Strength Index (RSI)
- 43.82
- Average Volume (3m)
- 84.50K
Important Dates
Daito Pharmaceutical Co., Ltd. upcoming earnings date is Jan 08, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 14, 2026
- Next Earnings Date
- Jan 08, 2027
- Ex-Dividend Date
- Nov 27, 2025
Financial Position
Daito Pharmaceutical Co., Ltd. as a current ratio of 2.62, with Debt / Equity ratio of 17.57%
- Current Ratio
- 2.62
- Quick Ratio
- 1.44
- Debt to Market Cap
- 0.21
- Net Debt to EBITDA
- 1.04
- Interest Coverage Ratio
- 27.98
Taxes
In the past 12 months, Daito Pharmaceutical Co., Ltd. has paid 928.00M in taxes.
- Income Tax
- 928.00M
- Effective Tax Rate
- 0.23
Enterprise Valuation
Daito Pharmaceutical Co., Ltd. EV to EBITDA ratio is 6.20, with an EV/FCF ratio of 7.91.
- EV to Sales
- 0.88
- EV to EBITDA
- 6.20
- EV to Free Cash Flow
- 7.91
- EV to Operating Cash Flow
- 4.66
Balance Sheet
Daito Pharmaceutical Co., Ltd. has JPY 1.69B in cash and marketable securities with JPY 8.45B in debt, giving a net cash position of -JPY 6.76B billion.
- Cash & Marketable Securities
- JPY 1.69B
- Total Debt
- JPY 8.45B
- Net Cash
- -JPY 6.76B
- Net Cash Per Share
- -JPY 234.21
- Tangible Book Value Per Share
- JPY 1,787.79
Margins
Gross margin is 19.24%, with operating margin of 6.76%, and net profit margin of 6.39%.
- Gross Margin
- 19.24%
- Operating Margin
- 6.76%
- Pretax Margin
- 8.02%
- Net Profit Margin
- 6.39%
- EBITDA Margin
- 14.24%
- EBIT Margin
- 7.83%
Analyst Forecast
The average price target for Daito Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -2.83%
- EPS Growth Forecast
- 65.69%
Scores
- Smart Score
- ―
- AI Score
- 67
